Durability of Infliximab Is Associated With Disease Extent in Children With Inflammatory Bowel Disease
暂无分享,去创建一个
J. Machan | N. LeLeiko | J. Shapiro | C. Cerezo | M. Herzlinger | L. Shalon | S. Subedi | A. Ross | J. Silverstein | V. Kasper
[1] C. Ponsioen,et al. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. , 2015, Gastroenterology.
[2] L. Peyrin-Biroulet,et al. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. , 2015, Journal of Crohn's & colitis.
[3] J. Gisbert,et al. Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failed , 2015, Alimentary pharmacology & therapeutics.
[4] B. Sands,et al. High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy. , 2015, Journal of Crohn's & colitis.
[5] A. Bousvaros,et al. Antibodies to Infliximab Are Associated with Lower Infliximab Levels and Increased Likelihood of Surgery in Pediatric IBD , 2015, Inflammatory bowel diseases.
[6] G. Rogler,et al. Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis? , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[7] C. Redmond,et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[8] E. Semikina,et al. Cytokine profile in children with inflammatory bowel disease , 2014, Biochemistry (Moscow).
[9] D. Mould,et al. Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study , 2014, Inflammatory bowel diseases.
[10] M. Dubinsky,et al. Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel Disease , 2014, Inflammatory bowel diseases.
[11] P. Lewindon,et al. Predictors of response to Infliximab in children with luminal Crohn's disease. , 2014, Journal of Crohn's & colitis.
[12] D. Schwartz,et al. Outcomes Following Infliximab Therapy for Pediatric Patients Hospitalized With Refractory Colitis–Predominant IBD , 2014, Journal of pediatric gastroenterology and nutrition.
[13] M. Färkkilä,et al. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. , 2013, Journal of Crohn's & colitis.
[14] L. Siproudhis,et al. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[15] L. Peyrin-Biroulet,et al. Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study , 2013, Inflammatory bowel diseases.
[16] D. Mould,et al. Anti‐TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics‐Based Dosing Paradigms , 2012, Clinical pharmacology and therapeutics.
[17] G. Porro,et al. Biologic Therapy for Inflammatory Bowel Disease , 2012, Drugs.
[18] A. Griffiths,et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension , 2011, Current medical research and opinion.
[19] A. Griffiths,et al. Outcome Following Infliximab Therapy in Children With Ulcerative Colitis , 2010, The American Journal of Gastroenterology.
[20] P. Rutgeerts,et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.
[21] M. Silverberg,et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis , 2009, Gut.
[22] A. Griffiths,et al. Long‐term outcome of maintenance infliximab therapy in children with Crohn's disease , 2009, Inflammatory bowel diseases.
[23] J. Gisbert,et al. Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review , 2009, The American Journal of Gastroenterology.
[24] A. Griffiths,et al. Review and clinical perspectives for the use of infliximab in ulcerative colitis. , 2008, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[25] M. Regueiro,et al. Infliximab dose intensification in Crohn's disease , 2007, Inflammatory bowel diseases.
[26] Paul Rutgeerts,et al. Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.
[27] An Carbonez,et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.
[28] S. Hanauer,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .